Dmitri Golberg of the National Institute for Materials Science in Tsukuba, Japan, and colleagues have demonstrated how functionalizing boron nitride (BN) nanotubes with mesoporous silica allows them to carry out intracellular delivery of chemotherapy agents.

The team has demonstrated proof of principle by loading up their BN@silica hybrids with the well-established anticancer drug, doxorubicin, commonly used in leukemia and lymphoma. The use of a nanotube host should allow much better targeting with such agents, which can have serious side effects. In the case of doxorubicin, life-threatening damage to the heart tissue can occur.

The team has shown that their hybrid improves the effectiveness of the drug in killing LNcap prostate cancer cells compared with unloaded nanotubes as controls.

Sign in Area

Additional Sign In options

Please note that to comment on an article you must be registered and logged in. Registration is for free, you may already be registered to receive, e.g., the newsletter.When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Our site uses cookies to improve your experience. You can find out more about our use of cookies
in our "standard cookie policy", including
instructions on how to reject and delete cookies if you wish to do so. By continuing to browse this site you agree
to us using cookies as described in our "standard cookie policy".

Our site uses cookies to improve your experience. You can find out more about our use of cookies
in our "standard cookie policy", including
instructions on how to reject and delete cookies if you wish to do so. By continuing to browse this site you agree
to us using cookies as described in our "standard cookie policy".